Innovative Therapeutics Platform Athebio specializes in designing tailor-made DARPins that enable drug developers to create next-generation targeted therapies with enhanced efficacy and safety, indicating a strong market for advanced biologics tools.
Strategic Collaborations Recent partnerships with leading biotech and gene therapy firms like 3T Biosciences and REGENXBIO highlight potential opportunities for service providers in collaborative research, platform integration, and innovative vector development.
Leadership Development The appointment of a new CEO signals possible expansion and strategic shifts, creating opportunities for engagement with leadership and consultancy firms focused on biotech growth strategies.
Growing Industry Presence With recognition as an innovation leader in ankyrin repeat protein discovery and design, Athebio presents potential for suppliers of biotech research tools, reagents, and platform support services.
Early Revenue Stage Operating with a revenue range of up to 1 million dollars, Athebio offers opportunities for early-stage investment, pilot collaborations, and customized technology solutions tailored to accelerating their R&D efforts.
Athebio AG uses 8 technology products and services including Squarespace, Open Graph, WordPress, and more. Explore Athebio AG's tech stack below.
| Athebio AG Email Formats | Percentage |
| First.Last@athebio.com | 100% |
Biotechnology ResearchZurich, Switzerland11-50 Employees
Athebio enables innovative drug developers to create superior targeted therapeutics of advanced efficacy and safety by providing them with tailor-made “plug and play” DARPins as building blocks, working together in a co-creative space, and supporting them with in-depth expertise.
Company Overview
Funding & FinancialsAthebio AG's revenue is estimated to be in the range of $1M
Funding & FinancialsAthebio AG's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com